Cargando…

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

AIMS/INTRODUCTION: To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 inhibitor on improving the glucose variability i...

Descripción completa

Detalles Bibliográficos
Autores principales: Miya, Aika, Nakamura, Akinobu, Cho, Kyu Yong, Kawata, Shinichiro, Nomoto, Hiroshi, Nagai, So, Sugawara, Hajime, Taneda, Shinji, Tsuchida, Kazuhisa, Omori, Kazuno, Yokoyama, Hiroki, Takeuchi, Jun, Aoki, Shin, Kurihara, Yoshio, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354506/
https://www.ncbi.nlm.nih.gov/pubmed/33325645
http://dx.doi.org/10.1111/jdi.13479
_version_ 1783736607327649792
author Miya, Aika
Nakamura, Akinobu
Cho, Kyu Yong
Kawata, Shinichiro
Nomoto, Hiroshi
Nagai, So
Sugawara, Hajime
Taneda, Shinji
Tsuchida, Kazuhisa
Omori, Kazuno
Yokoyama, Hiroki
Takeuchi, Jun
Aoki, Shin
Kurihara, Yoshio
Atsumi, Tatsuya
Miyoshi, Hideaki
author_facet Miya, Aika
Nakamura, Akinobu
Cho, Kyu Yong
Kawata, Shinichiro
Nomoto, Hiroshi
Nagai, So
Sugawara, Hajime
Taneda, Shinji
Tsuchida, Kazuhisa
Omori, Kazuno
Yokoyama, Hiroki
Takeuchi, Jun
Aoki, Shin
Kurihara, Yoshio
Atsumi, Tatsuya
Miyoshi, Hideaki
author_sort Miya, Aika
collection PubMed
description AIMS/INTRODUCTION: To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. MATERIALS AND METHODS: A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was carried out in a multicenter, prospective, randomized, parallel‐group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C‐peptide (CPR) divided at baseline by the median. RESULTS: ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (−29.2 ± 28.3 vs −20.0 ± 24.6, respectively; P = 0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P < 0.01). CONCLUSIONS: COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion.
format Online
Article
Text
id pubmed-8354506
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83545062021-08-15 Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin Miya, Aika Nakamura, Akinobu Cho, Kyu Yong Kawata, Shinichiro Nomoto, Hiroshi Nagai, So Sugawara, Hajime Taneda, Shinji Tsuchida, Kazuhisa Omori, Kazuno Yokoyama, Hiroki Takeuchi, Jun Aoki, Shin Kurihara, Yoshio Atsumi, Tatsuya Miyoshi, Hideaki J Diabetes Investig Articles AIMS/INTRODUCTION: To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. MATERIALS AND METHODS: A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was carried out in a multicenter, prospective, randomized, parallel‐group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C‐peptide (CPR) divided at baseline by the median. RESULTS: ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (−29.2 ± 28.3 vs −20.0 ± 24.6, respectively; P = 0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P < 0.01). CONCLUSIONS: COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion. John Wiley and Sons Inc. 2021-01-21 2021-08 /pmc/articles/PMC8354506/ /pubmed/33325645 http://dx.doi.org/10.1111/jdi.13479 Text en © 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Miya, Aika
Nakamura, Akinobu
Cho, Kyu Yong
Kawata, Shinichiro
Nomoto, Hiroshi
Nagai, So
Sugawara, Hajime
Taneda, Shinji
Tsuchida, Kazuhisa
Omori, Kazuno
Yokoyama, Hiroki
Takeuchi, Jun
Aoki, Shin
Kurihara, Yoshio
Atsumi, Tatsuya
Miyoshi, Hideaki
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
title Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
title_full Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
title_fullStr Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
title_full_unstemmed Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
title_short Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
title_sort impact of endogenous insulin secretion on the improvement of glucose variability in japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354506/
https://www.ncbi.nlm.nih.gov/pubmed/33325645
http://dx.doi.org/10.1111/jdi.13479
work_keys_str_mv AT miyaaika impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT nakamuraakinobu impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT chokyuyong impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT kawatashinichiro impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT nomotohiroshi impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT nagaiso impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT sugawarahajime impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT tanedashinji impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT tsuchidakazuhisa impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT omorikazuno impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT yokoyamahiroki impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT takeuchijun impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT aokishin impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT kuriharayoshio impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT atsumitatsuya impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin
AT miyoshihideaki impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin